This condition is characterized by microangiopathic hemolytic anemia and thrombocytopenia, which can result from either an acquired deficiency of the ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) or through complement-mediated mechanisms. This evidence concerns the gene ADAMTS13 and Thrombocytopenia.